Erythropoietin administration during radiotherapy in anaemic head-and-neck cancer patients: Is it still a reasonable option or too dangerous?

Oral Oncology

Volumn 45, Issue 2, 2009, Pages 91-93

  Rades, Dirk ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD VISCOSITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; EDITORIAL; ESOPHAGUS CANCER; FATIGUE; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CANCER; LARYNX CANCER; LUNG NON SMALL CELL CANCER; MOUTH CANCER; OROPHARYNX CANCER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RADIOBIOLOGY; TUMOR GROWTH; UTERUS CANCER;

ANEMIA; CELL HYPOXIA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEAD AND NECK NEOPLASMS; HUMANS; RADIOTHERAPY;

EID: 58549106120     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2008.03.015     Document Type: Editorial

References (21)

1. Henry D.H., and Abels R.I. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anaemia: results of double-blind and open-label follow up studies. Semin Oncol 21 (1994) 21-28
2. Vaupel P., Thews O., and Hockel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 18 (2001) 243-259
3. Vaupel P., Thews O., Mayer A., Hockel S., and Hockel M. Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level?. Strahlenther Onkol 178 (2002) 727-731
4. Rades D., Tribius S., Yekebas E.F., et al. Epoetin alfa improves survival after chemoradiation for stage III esophageal cancer: final results of a prospective observational study. Int J Radiat Oncol Biol Phys 65 (2006) 459-465
5. Blohmer J.U., Wurschmidt F., Petry U., et al. 6th Interim analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study: sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for patients with high-risk cervical cancer (Abstr). Proc Am Soc Clin Oncol 22 (2003) 447
6. Cmelak A.J., Li S., Goldwasser M.A., et al. Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern cooperative oncology group study E2399. J Clin Oncol 25 (2007) 3971-3977
7. Crawford J., Robert F., Perry M.C., Belani C., and Williams D. A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy. J Thorac Oncol 2 (2007) 210-220
8. Grote T., Yeilding A.L., Castillo R., et al. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 23 (2005) 9377-9386
9. Vansteenkiste J., Pirker R., Massuti B., et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Nat Cancer Inst 94 (2002) 1211-1220
10. Machtay M., Pajak T.F., Suntharalingam M., et al. Radiotherapy with or without erythropoietin for anaemic patients with head and neck cancer: a randomized trial of the radiation therapy oncology group (RTOG 99-03). Int J Radiat Oncol Biol Phys 69 (2007) 1008-1017
11. Henke M., Laszig R., Rube C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
12. Rizzo J.D., Somerfield M., Hagerty K.L., et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 26 (2008) 132-149
13. Bokemeyer C., Aapro M.S., Courdi A., et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43 (2007) 258-270
14. Leyland-Jones B., Semiglazov V., Pawlicki M., et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly non-anaemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23 (2005) 5960-5972
15. Wright J.R., Ung Y.C., Julian J.A., et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25 (2007) 1027-1032
16. Goldberg P. Study finds more deaths on Aranesp arm in cancer anemia study, no benefit seen [newsletter]. Cancer Lett 33 (2007) 1
17. Leyland-Jones B. Investigators BEST study group: breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4 (2003) 459-460
18. ® for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) - the Danish head and neck cancer group DAHANCA 10 randomized trial. Eur J Cancer Suppl 5 No.6 (2007) 7
19. Henke M., Mattern D., Pepe M., et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J Clin Oncol 24 (2006) 4708-4713
20. Acs G., Xu X., Chu C., Acs P., and Verma A. Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer 100 (2004) 2376-2386
21. Rades D., Gohlke H., Schild S.E., and Kilic E. The impact of tumor expression of erythropoietin receptors (Epo-R) and erythropoietin (Epo) on clinical outcome of esophageal cancer patients treated with chemoradiation. Int J Radiat Oncol Biol Phys 71 (2008) 152-159